PEG-MGF

The IGF-1 gene is spliced into several transcripts. One of them, IGF-1Ec in humans, is induced in skeletal muscle by mechanical loading and by damage, and Geoffrey Goldspink's group named it mechano growth factor [5]. A 49-base-pair insert in the human transcript shifts the reading frame and produces a distinct E domain, which is what makes MGF different from ordinary IGF-1 [2].

What is actually sold. Not the protein. The research compound, and the black-market product, is a synthetic peptide corresponding to the last 24 amino acids of that E domain [1]. PEG-MGF is that peptide with a polyethylene glycol chain attached — a standard trick for slowing renal clearance of small peptides. There is no published study of the PEGylated version. Not a pharmacokinetic study, not an animal experiment, nothing. Everything below is about the unmodified E peptide.

The good result. In primary human muscle cell cultures from donors of different ages, the MGF-24aa-E peptide significantly increased proliferative lifespan, delayed senescence and raised fusion potential. The authors framed it as a way to fight age-related sarcopenia without IGF-1's oncogenic baggage [2]. This is a good, careful experiment on human cells and it is the strongest thing in the file.

The catch in the same paper. The effect on proliferative lifespan was seen in cells from neonatal and young adult muscle — and not in cells from old adult muscle [2]. The one population for whom a satellite-cell activator would matter most is the one where it did not work.

Everything else. In mice, E-domain peptide delivered from implanted polymer microrods after coronary artery ligation reduced mortality and slowed cardiac decompensation over ten weeks [6] — a striking result, obtained with a localised delivery device, not an injection. In growth plate cartilage, where MGF is expressed, adding the peptide did nothing to chondrocyte proliferation [7]. In healthy young men, two weeks of recombinant growth hormone tripled circulating IGF-I but left muscle MGF transcript levels unchanged, with or without resistance exercise [8] — relevant to anyone assuming GH and MGF are two taps on the same pipe.

Human evidence. None for MGF, and none for PEG-MGF. The substance has been prohibited by WADA since 2005 [5], and a 2026 review of self-administered GH–IGF-1 axis peptides places it with the rest of the group: circulating well ahead of the clinical evidence [9].

The E peptide is not a shorter IGF-1. In human prostate cancer cells, silencing the IGF-1 receptor and the insulin receptor by siRNA left the peptide's mitogenic activity and its ERK1/2 signalling intact, ruling out IGF-1R, IR and the hybrid receptor as the route [3]. That is a genuinely interesting finding and it is also the central unknown: after two decades, the receptor the E peptide acts on has not been identified [1].

In muscle, the proposed role is sequential. Mechanical damage switches on the IGF-1Ec splice, the E peptide activates satellite cells to proliferate and delay differentiation, and the IGF-1Ea isoform then drives the fusion and hypertrophy stage [2][10]. The synthetic peptide is an attempt to supply the first half of that sequence on demand.

PEGylation adds nothing mechanistic. It is a pharmacokinetic intervention: attaching PEG raises hydrodynamic radius and slows renal filtration, which for a PEGylated rhIGF-I stretched the half-life to 140-200 hours and, incidentally, blunted the feedback suppression of growth hormone and the hypoglycaemia that unmodified rhIGF-I caused [11]. The same literature notes the standard trade-off — PEGylation "frequently comes at the cost of reduced bioactivity" — which is why conjugates have been engineered with protease-cleavable linkers to release native protein in the target tissue [12]. Whether a PEG chain on a 24-residue peptide preserves its activity is not known, because nobody has published the experiment.

Three different things travel under the name MGF and they are not interchangeable. The full-length IGF-1Ec protein; the synthetic 24-residue E-domain peptide used in essentially all the published pharmacology [1]; and PEG-MGF, the E peptide with polyethylene glycol attached, which appears in no published study.

A fourth version has been documented in the illicit supply. In 2014 a "full-length MGF" offered to athletes was characterised by mass spectrometry: a 12,264.9 Da protein closely related to IGF-1Ec, but with the terminal lysine removed and an R109H substitution — that is, not the human sequence [5]. Detection methods for it were built into routine doping control down to 0.25 ng/mL.

No human safety data exist for MGF in any form, and no safety data of any kind exist for PEG-MGF.

The cancer question is not hypothetical here. IGF-1Ec is preferentially expressed in human prostate cancer and in prostatic intraepithelial neoplasia, while normal prostate epithelial cells do not express it at all, and adding the synthetic E peptide to prostate cancer cell lines stimulated their growth [3]. IGF-1Ec expression rises with increasing dysplasia in colonic polyps and is significantly higher in colorectal cancer than in normal colon [4], and the isoform has a review literature of its own in osteosarcoma [13]. These are expression and cell-culture findings, not evidence that injecting the peptide causes cancer in people — but the marketing claim that MGF gives IGF-1's benefits "without the oncogenic side effects" [2] is contradicted by the peptide's own literature.

The unidentified receptor. Because the target has never been found [1][3], there is no way to reason about what else the peptide might hit, and no receptor-occupancy basis for choosing a dose.

Product quality. A product sold to athletes as full-length MGF was found to carry a point substitution and a truncated C terminus relative to the human sequence [5].

No interaction data exist. The one relevant human measurement is negative in an informative way: two weeks of recombinant growth hormone in healthy young men raised circulating IGF-I from 31.8 to 109 nmol/L but did not change muscle MGF transcript expression, with or without an acute bout of heavy resistance exercise [8]. Growth hormone and MGF are not simply two ways of turning the same dial.